英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：

hairs    音标拼音: [h'ɛrz]

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate . . .
    Lutetium-177 (177 Lu)–PSMA-617 is a radioligand therapy that delivers beta-particle radiation to PSMA-expressing cells and the surrounding microenvironment Methods
  • 177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant . . .
    Waterfall plots of A PSA responses (percentage change from baseline value) after the first 177 Lu-PSMA-617 cycle and B best PSA responses to the overall course of 177 Lu-PSMA-617 RLT for the entire cohort (N = 254) PD, [biochemical] progressive disease; PR, [biochemical] partial response; RLT, radioligand therapy; SD, [biochemical] stable disease
  • Novartis announces positive result of phase III study with radioligand . . .
    177 Lu-PSMA-617 is an investigational PSMA-targeted radioligand therapy for metastatic castration-resistant prostate cancer It is a type of precision cancer treatment combining a targeting compound (ligand) with a therapeutic radioisotope (a radioactive particle) 1 0 -1 2
  • 177 Lu-PSMA Radioligand Therapy for Prostate Cancer
    Abstract 177 Lu-prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) using inhibitors of PSMA is a novel therapeutic option in patients with metastatic castration-resistant prostate cancer The current literature suggests that this therapy is well tolerated and effective On the basis of clinical need and current evidence, the therapy is being implemented in a growing number of
  • PSMA-Targeted Therapy Is a Game Changer in Prostate Cancer Treatment . . .
    Dr Karine Tawagi Key Points: Lutetium-177-PSMA-617 (LuPSMA) is a prostate-specific membrane antigen (PSMA)–targeted radioligand therapy currently approved for patients with metastatic castration-resistant prostate cancer (mCRPC) following treatment with a prior androgen receptor signaling inhibitor (ARSI) and taxane chemotherapy
  • Prostate-Specific Membrane Antigen Radioligand Therapy Using 177Lu-PSMA . . .
    The objective of this study was to determine the safety, kinetics, and dosimetry of the 177 Lu-labeled prostate-specific membrane antigen (PSMA) small molecules 177 Lu-PSMA I T and 177 Lu-PSMA-617 in a large cohort of patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing PSMA radioligand therapy (PRLT) Methods: In total, 138 patients (mean age, 70 ± 9 y; age range
  • FDA Approved Pluvicto (177Lu-PSMA-617) for Metastatic Castration . . .
    Pluvicto is a targeted radioligand therapy designed to deliver a lethal dose of radiation directly to PSMA-expressing cancer cells while sparing surrounding healthy tissue The treatment consists of Lutetium-177 (177Lu), a beta-emitting radioactive isotope, bound to a PSMA-targeting small molecule
  • Status of PSMA-targeted radioligand therapy in prostate cancer: current . . .
    Just one RLT involving PSMA has been approved thus far for patients with advanced prostate cancer, lutetium-177–PSMA-617 (177 Lu-PSMA-617, also known as lutetium-177 vipivotide tetraxetan), based on the phase III VISION trial (NCT03511664) 15 This trial randomized 831 patients from 84 sites across North America and Europe in a 2:1 ratio (551
  • ASCO 2025: How to Get Lutetium-177 PSMA to Those That Will Most Benefit?
    Lutetium-177–PSMA-617 is a targeted radioligand therapy directed against prostate-specific membrane antigen (PSMA), a surface protein expressed on most prostate cancer cells and, to a lesser extent, some benign tissues contributing to the treatment’s toxicity profile
  • Cost-Effectiveness Analysis of 177 Lu-PSMA-617 Radioligand Therapy in . . .
    Background: Metastatic castration-resistant prostate cancer poses a therapeutic challenge with poor prognosis The VISION trial showed prolonged progression-free and overall survival in patients treated with lutetium Lu 177 vipivotide tetraxetan (177Lu-PSMA-617) radioligand therapy compared with using the standard of care (SoC) alone The objective of this study was to determine the cost





中文字典-英文字典  2005-2009